To ask the Secretary of State for Health and Social Care, if he will make an assessment of the implications for his policies on covid-19 vaccinations of the study by Fraiman, J., et al., entitled Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults published in the journal Vaccine on 22 September 2022.

Each COVID-19 vaccine candidate is assessed by teams of scientists and clinicians and only authorised once it has met robust standards of safety, quality, and effectiveness set by the Medicines and Healthcare products Regulatory Agency (MHRA).

The MHRA and the UK Health Security Agency continuously monitor the safety of all COVID-19 vaccines, including through reviewing all suspected Adverse Drug Reaction reports, and other data from the United Kingdom and internationally. Since the start of the pandemic, the National Institute for Health and Care Research has also allocated more than £110 million in funding for COVID-19 vaccine research, including consideration of vaccine safety.